Orphazyme is a biopharmaceutical company developing the Heat-Shock Protein (HSPs) response for the treatment of neurodegenerative orphan diseases which are characterized by protein misfolding, aggregation and lysosomal dysfunction. Co. focusses on rare, neurodegenerative disorders (including neuropathic lysosomal diseases (LSDs) and progressive neuromuscular disorders). Co.'s primary investigational product candidate, arimoclomol, amplifies endogenous HSPs, which are at the core of the Heat-Shock Response (HSR) and help guard against toxicity caused by protein misfolding and lysosomal dysfunction. Co. is also evaluating opportunities in disorders such as GCase-deficient Parkinson's disease. The ORPH stock yearly return is shown above.
The yearly return on the ORPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ORPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|